Exchange: NASDAQ·Updated 04:10 PM EST

LYEL News

News
all
press releases
Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 148.3% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 148.3% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
More News
Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma (NASDAQ:LYEL) shares movedread more...
Benzinga
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.read more...
Benzinga
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Lyell Immunopharma reports improved safety data for LYL273 in metastatic colorectal cancer and advances study to Phase 1/2 design.read more...
Benzinga
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks
Lyell Immunopharma (NASDAQ:LYEL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-lyell-immunopharma-inc-stock...
MarketBeat

Advertisement|Remove ads.